Skip to content

Clinical and Radiographic Evaluation of Bioceramic Putty MTA Versus MTA in Pulpotomy of Immature Permanent Molars

Clinical and Radiographic Evaluation of Bioceramic Putty Mineral Trioxide Aggregate Versus Mineral Trioxide Aggregate in Pulpotomy of Immature Permanent Molars: A Randomized Clinical Trial

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06219824
Acronym
MTA
Enrollment
40
Registered
2024-01-23
Start date
2024-11-01
Completion date
2025-11-30
Last updated
2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Caries, Pulpotomy

Keywords

Immature permanent molars,, young permenent molars, pulpotomy, vital pulp therapy, deep caries, Putty MTA, bioceramic MTA

Brief summary

The present study aims to evaluate the clinical and radiographic success of bioceramics putty MTA versus MTA in the pulpotomy of immature permanent molars The main question it aims to answer is: Will the biocermaics putty MTA have higher clinical and radiographic success rates than MTA in pulpotomy of immature permanent molars?

Detailed description

limited clinical trials have reported the clinical and radiographic outcomes after pulpotomy with premixed putty bioceramic MTA and conventional MTA in young permanent molars. MTA has various drawbacks, such as difficulty in handling, long setting time, discoloration of the tooth, and its form as a powder/liquid which raise the responsibility for major material waste. To conquer these issues, bioceramic materials have been developed premixed putty bioceramic MTA is a ready-to-use material for immediate placement with zero waste, saving cost and chair time. Thus, the present study aims to evaluate bioceramic putty MTA's clinical and radiographic success versus MTA in pulpotomy of immature permanent molars.

Interventions

pulpotomy treatment will be done and the premixed bioceramic MTA will be applied in the pulp chamber

DRUGConventional MTA

pulpotomy treatment will be done and powder and liquid MTA will be mixed and applied in the pulp chamber

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 8 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients aged from 6-8 years of both sexes have immature permanent molars * with deep carious lesions indicated for pulpotomy. * Restorable young permanent molars with no clinical symptoms of irreversible pulpitis. * Permanent molars without any clinical sign of pulp necrosis including swelling, fistula, pain on percussion, and pathologic tooth mobility. * Permanent molars without any adverse radiographic findings including thickening of the periodontal ligament space, radiolucency at the interradicular or periapical regions * permanent molars without internal and external root resorption, or calcification in pulp tissue.

Exclusion criteria

* Medically compromised patients who have systemic disease. * Uncooperative patients who refuse treatment. * Permanent molars that were previously restored.

Design outcomes

Primary

MeasureTime frameDescription
Primary Outcome24hrs, 1 weekImmediate Postoperative pain \[ Time Frame: one week) post operative pain by Verbal analogue scale.It is a 10 cm long horizontal line with points labeled from 0 to 10 where (0) indicates no pain, (1-3) mild pain, (4-6) moderate pain, and (7-10) severe pain.

Secondary

MeasureTime frameDescription
Secondary outcome6,12 monthThe increase in root length, The root lengthening will be assessed in Mm through Digora software

Countries

Egypt

Contacts

Primary ContactMarwa Ad Hussien, MSD
marwa.hussien@dentistry.cu.edu.eg01222156972

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026